A Combination of Adrenaline with an Antidepressant for Use in the Treatment of Shocks

Abstract

The present invention concerns a novel combination of adrenalin with an antidepressant and its use as a pharmaceutical composition for the treatment of shocks. The pharmaceutical composition is to be administered by injection.

1 . An aqueous solution comprising adrenalin and an antidepressant, wherein the antidepressant is chosen from the group consisting of amitriptyline, amoxapine, amitriptylinoxide, butriptyline, clomipramine, demexiptiline, dibenzepin, dimetacrine, dosulepin, doxepin, imipraminoxide, lofepramine, maprotiline, mianserin, melitracen, metapramine, nitroxazepine, nortriptyline, noxiptiline, pipofezine, propizepine, protriptyline, quinupramine, amineptine and trimipramine, or one of its pharmaceutically acceptable salts. 
     
     
         2 . The solution according to  claim 1 , further comprising at least one preservative agent. 
     
     
         3 . The solution according to  claim 1 , wherein the antidepressant is doxepin or one of its pharmaceutically acceptable salts. 
     
     
         4 . The solution according to  3   claim 1 , wherein adrenalin is at a concentration comprised between 0.05 mg/ml and 1.0 mg/ml in said solution. 
     
     
         5 . The solution according to  claim 1 , wherein the antidepressant is at a concentration comprised between 0.1 mg/ml and 10 mg/ml in said solution. 
     
     
         6 . The solution according to  claim 1 , consisting of adrenalin, an antidepressant, sodium chloride, a preservative agent and water. 
     
     
         7 . The aqueous solution according to  claim 1  for use in the treatment of shocks. 
     
     
         8 . An aqueous solution comprising adrenalin and an antidepressant for use in the treatment of shocks. 
     
     
         9 . The aqueous solution according to  claim 8  for use in the treatment of a shock selected from the group consisting of: anaphylactic shock, cardiac arrest, and cardiovascular distress associated with anaphylactic shock, hemorragic shock, traumatic shock, infectious shock and secondary shock due to cardiac surgery. 
     
     
         10 . A pharmaceutical composition comprising the solution according to  claim 8 . 
     
     
         11 . The pharmaceutical composition according to  claim 10 , for use in the treatment of shocks. 
     
     
         12 . The pharmaceutical composition according to  claim 10 , wherein the solution is suitable for intramuscular injection and/or subcutaneous injection. 
     
     
         13 . The pharmaceutical composition for use according to  claim 12 , comprising administering a dose of adrenalin comprised between 0.05 mg and 0.30 mg. 
     
     
         14 . The pharmaceutical composition for use according to  claim 12 , comprising administering the antidepressant at a dose comprised between 0.1 mg and 3 mg. 
     
     
         15 . An auto-injection device comprising the pharmaceutical composition according to  claim 10 . 
     
     
         16 . The auto-injection device comprising the pharmaceutical composition which comprises a container prefilled with the pharmaceutical composition according to  claim 10 . 
     
     
         17 . An auto-injection device comprising the pharmaceutical composition comprising two containers wherein one container is prefilled with an aqueous solution of adrenalin, the other one container is prefilled with an aqueous solution of an antidepressant and wherein the pharmaceutical composition according to  claim 10  is formed by mixing the two solutions within the device. 
     
     
         18 . The aqueous solution according  claim 7  for use in the treatment of a shock selected from the group consisting of: anaphylactic shock, cardiac arrest, and cardiovascular distress associated with anaphylactic shock, hemorragic shock, traumatic shock, infectious shock and secondary shock due to cardiac surgery. 
     
     
         19 . A pharmaceutical composition comprising the solution according to  claim 1 . 
     
     
         20 . The pharmaceutical composition according to  claim 19 , for use in the treatment of shocks. 
     
     
         21 . The pharmaceutical composition according to  claim 19 , wherein the solution is suitable for intramuscular injection and/or subcutaneous injection. 
     
     
         22 . The pharmaceutical composition for use according to  claim 21 , comprising administering a dose of adrenalin comprised between 0.05 mg and 0.30 mg. 
     
     
         23 . The pharmaceutical composition for use according to  claim 21 , comprising administering the antidepressant at a dose comprised between 0.1 mg and 3 mg. 
     
     
         24 . An auto-injection device comprising the pharmaceutical composition according to  claim 19 . 
     
     
         25 . The auto-injection device comprising the pharmaceutical composition which comprises a container prefilled with the pharmaceutical composition according to  claim 19 . 
     
     
         26 . An auto-injection device comprising the pharmaceutical composition comprising two containers wherein one container is prefilled with an aqueous solution of adrenalin, the other one container is prefilled with an aqueous solution of an antidepressant and wherein the pharmaceutical composition according to  claim 19  is formed by mixing the two solutions within the device.